PMID- 25611245
OWN - NLM
STAT- MEDLINE
DCOM- 20160830
LR  - 20220408
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 23
IP  - 10
DP  - 2015 Nov-Dec
TI  - Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the 
      Differential Diagnosis of Invasive Urothelial Carcinoma.
PG  - 711-6
LID - 10.1097/PAI.0000000000000143 [doi]
AB  - Distinguishing between invasive urothelial carcinoma from other genitourinary 
      lesions such as prostatic and renal carcinomas can be difficult, and may require 
      highly sensitive immunohistochemical markers. GATA-binding protein 3 (GATA3) has 
      been reported in a high percentage of urothelial and breast carcinomas. Mouse 
      monoclonal uroplakin II (UPII) and p40 antibodies have recently been developed 
      and demonstrated high specificity in urothelial carcinoma. This study evaluated 
      the immunohistochemical staining sensitivities of UPII, GATA3, p40, and p63 in 
      the detection of invasive urothelial carcinoma. UPII, GATA3, and p40 were further 
      tested for specificity in lung, breast, colon, kidney, and prostate cancers. In 
      all invasive urothelial carcinoma cases, UPII, GATA3, p40, and p63 exhibited 
      sensitivities of 77.7%, 83.5%, 85.4%, and 80.6%, respectively. The combination of 
      UPII, GATA3, and p40 antibodies stained 94.2% (97/103) of all invasive urothelial 
      carcinoma cases, including 92.2% (71/77) of grade 2-3 urothelial carcinomas. In 
      addition, GATA3 and UPII showed negative staining in lung squamous cell 
      carcinomas and p40 showed negative staining in breast infiltrating ductal 
      carcinomas. The combination of UPII, GATA3, and p40 showed negative staining in 
      lung adenocarcinoma, colon adenocarcinoma, and renal carcinomas. In conclusion, 
      UPII, GATA3, and p40, when used in combination, are highly sensitive in the 
      differential diagnosis of invasive urothelial carcinoma.
FAU - Hoang, Laura L
AU  - Hoang LL
AD  - *Department of Research and Development, Biocare Medical LLC, Concord, CA daggerMercy 
      Hospital & Trauma Center, Mercy Health System, Janesville, WI double daggerDepartment of 
      Pathology and Laboratory Medicine, Indiana University School of Medicine, 
      Indianapolis, IN.
FAU - Tacha, David
AU  - Tacha D
FAU - Bremer, Ryan E
AU  - Bremer RE
FAU - Haas, Thomas S
AU  - Haas TS
FAU - Cheng, Liang
AU  - Cheng L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
RN  - 0 (TP63 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (UPK2 protein, human)
RN  - 0 (Uroplakin II)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Biomarkers, Tumor/*immunology
MH  - Diagnosis, Differential
MH  - Female
MH  - GATA3 Transcription Factor/*immunology
MH  - Humans
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Transcription Factors/*immunology
MH  - Tumor Suppressor Proteins/*immunology
MH  - *Urologic Neoplasms/immunology/pathology
MH  - Uroplakin II/*immunology
MH  - *Urothelium/immunology/pathology
EDAT- 2015/01/23 06:00
MHDA- 2016/08/31 06:00
CRDT- 2015/01/23 06:00
PHST- 2015/01/23 06:00 [entrez]
PHST- 2015/01/23 06:00 [pubmed]
PHST- 2016/08/31 06:00 [medline]
AID - 10.1097/PAI.0000000000000143 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2015 Nov-Dec;23(10):711-6. doi: 
      10.1097/PAI.0000000000000143.